Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases

Lead Drug Candidate Targets TSLP Receptor For Asthma, Other Indications

 
• By Mandy Jackson

Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases. 

Lung health vector illustration
Upstream is focused on immune-mediated diseases, including asthma • Source: Shutterstock

More from Financing

More from Business